In April, the American Psychiatric Association (APA) released a comprehensive treatment guideline for treating adults who have been diagnosed with schizophrenia. Titled "The Practice Guideline for ...
3don MSN
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Study links hallucinogen use to higher schizophrenia risk, highlighting the need for caution and informed decisions on ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...
Researchers have found that repetitive transcranial magnetic stimulation (rTMS) can efficiently reduce the symptoms of ...
A new study involving almost 7 million health records has found that males are more exposed to the effect of cannabis use disorder on schizophrenia than females. This study represents a step ...
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...
The APA Guideline notes that "antipsychotic medications are indicated for nearly all acute psychotic episodes in patients with schizophrenia." (See Table II, Evidence of Efficacy: Highlights of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback